To estimate the possibility of long-term effects of subclinical thyroid dysfunction on hypertension and other cardiovascular-related conditions during pregnancy.
T hyroid hormones have a number of actions on cardiovascular physiology and blood pressure regulation, which are mediated by genomic mechanisms that cause ventricular remodeling or by direct effects. In most cases, cardiovascular aberrations follow long-term exposure to excessive or decreased hormone levels. [1] [2] [3] The effects of long-standing subclinical thyroid disorders are less well-studied, and there has been vigorous debate for many decades whether either contributes significantly to long-term cardiovascular morbidity. 4 -11 Also, it has been shown that individuals with subclinical hypothyroidism have impaired endothelium-derived vasodilatation from diminished nitric oxide secretion that is restored after thyroxine (T 4 ) replacement. 12 Possible adverse effects on pregnancy outcomes related to these subclinical thyroid disorders had renewed interest after publication of two landmark studies in 1999. 13, 14 Both of these investigations were of limited size and were specifically concerned with the effects of thyroid hormone deficiency on early fetal brain development. Subsequently, a number of large population-based studies that were designed to investigate any adverse effects on subclinical thyroid hormone disorders. [15] [16] [17] [18] [19] [20] [21] [22] [23] In a study that included a smaller cohort of women, including only women screened before 20 weeks of gestation, we did not find a relationship between subclinical hypothyroidism and pregnancy-associated hypertension. 16 In another study from our group, although we found a possible protective relationship between subclinical hyperthyroidism and pregnancy-associated hypertension, we did not control for the important confounder of maternal weight. 17 In addition to these studies suggesting a possible link with subclinical thyroid dysfunction and pregnancy-associated hypertension, there is further evidence of vascular-related sequelae. Specifically, autoimmune thyroid disorders have been associated with an increased risk for placental abruption.
These observations, when coupled with the pathologic cardiovascular effects of overtly abnormal increased or decreased thyroid hormone production, prompted the current study to further investigate the relationship between hypertensive disorders and subclinical thyroid dysfunction in a larger cohort, including women who presented for prenatal care after 20 weeks of gestation.
MATERIALS AND METHODS
This is another secondary analysis of a prospectively collected database initially designed to estimate normative values for thyroid hormone analytes in a large population of pregnant women. 16, 17 The protocol was approved by the Institutional Review Boards of the University of Texas Southwestern Medical Center and Parkland Hospital. The details of this process and the thyroid-analyze assays have been previously described. 16 -18 Briefly, excess serum obtained for prenatal serologic screening from November 1, 2000 to April 14, 2003 , was delivered to our immunochemistry research laboratory for thyroid analyte studies. Using a chemiluminescent assay (Immulite 2000 Analyzer), serum concentrations were determined for thyrotropin (TSH) and free T 4 . Women identified to have abnormal TSH levels had serum free T 4 reflexively determined, and if it was either abnormally high or low, then they were contacted and referred to an obstetrical complications clinic for further evaluation and possible treatment of overt thyroid dysfunction. These women were excluded from study, whereas all other women were enrolled in the prospective cohort.
For the purposes of the current study, normal values were considered to be those that comprised the range from the 2.5 th to 97.5 th percentiles for the entire cohort. For TSH, these values were 0.03 to 4.13 milliunits/L and for free T 4 these values ranged from 0.9 to 2.0 ng/dL. All women screened and delivered at Parkland Hospital and without evidence of overt thyroid dysfunction were included. Other inclusion criteria were subsequent delivery of a singleton neonate weighing 500 g or more. Women with serum TSH values within the normal range were considered to be euthyroid. Those with an abnormally low TSH but normal free T 4 levels were classified as having subclinical hyperthyroidism. Conversely, women with abnormally high TSH but normal free T 4 levels were classified as having subclinical hypothyroidism.
Pregnancy outcomes were retrieved from the computerized perinatal database that has been previously described. 16 -18 These data are routinely entered for all women at the time of their delivery at Parkland Hospital. For this study, the incidence of pregnancyassociated hypertensive disorders were compared for the three cohorts described. Hypertensive disorders were defined and classified according to a previously described protocol. 25 Briefly, gestational hypertension was defined as persistent blood pressures of 140/90 mm Hg or more, occurring after 20 weeks of gestation, without evidence of proteinuria. Mild preeclampsia was diagnosed in hypertensive women who also had 1ϩ proteinuria determined by urine dipstick analysis from a catheterized sample as per the protocol of our institution. Severe preeclampsia was diagnosed in hypertensive women with any of the following: 2ϩ or more proteinuria by dipstick from a catheterized urine sample, blood pressure higher than 160/110 mm Hg, persistent headache, visual disturbances, right upper quadrant or epigastric pain, serum creatinine 1.2 mg/mL or more, serum aspartate transaminase levels more than twice the upper limit of normal, or thrombocytopenia less than 100,000/mL.
Statistical analyses included Pearson 2 , CochranArmitage 2 for trend, analysis of variance, and logistic regression. When the three-group omnibus tests were statistically significant, contrast analyses were used to examine two-group comparisons and isolate significance of difference. Multivariable analyses were included to adjust for the effect modifiers of maternal age and weight as continuous measures, and categorical effects of race (as African American, white, Hispanic, other) and parity (as 0, 1, 2, more than 2). Statistical computations were performed with SAS 9.2 and two-sided PϽ.05 was considered statistically significant.
RESULTS
During the 30-month study, a total of 24,883 women who delivered singleton neonates weighing more than 500 g were included in this study. Of these, 23,771 (95.5%) had TSH values within the normal range and were considered to be euthyroid; 528 (2.1%) had TSH levels more than 4.13 milliunits/L along with normal free T 4 levels, therefore meeting criteria for subclinical hypothyroidism. The remaining 584 (2.3%) had TSH levels less than 0.03 milliunits/L along with normal free T 4 levels, therefore meeting criteria for subclinical hyperthyroidism. Maternal demographics of the three cohorts are shown in Table 1 , in which women within either the subclinical hyperthyroid cohort or the hypothyroid cohort were compared with those in the euthyroid cohort.
The incidences of pregnancy-associated hypertensive disorders as well as mild and severe preeclampsia were compared between the three study cohorts. In general, as the serum TSH level increased in the entire population, the incidence of hypertensive disorders increased concomitantly (P for trend, Pϭ.004). This relationship is shown in Figure 1 , in which subclinical hyperthyroid women who had the lowest TSH levels had an incidence of hypertensive disorders of 6.2% compared with 8.5% of euthyroid women and 10.9% of subclinical hypothyroid women. These differences when unadjusted were significant (Pϭ.016). These were then adjusted for maternal age, race, parity, and weight using logistic regression. Shown in Figure 2 are the adjusted odds ratios when the risks for hypertensive disorders were compared between the three cohorts. After adjustments, the only remaining significant association was in the cohort of women with subclinical hypothyroidism who were at increased risk for severe preeclampsia (adjusted odds ratio 1.6, 95% confidence interval 1.1-2.4; P ϭ.031).
DISCUSSION
The one salient finding of this study that included nearly 25,000 pregnant women was that those identified to have subclinical hypothyroidism had a significantly increased risk for development of severe preeclampsia when compared with euthyroid women. This association is particularly strong because its significance persisted after adjustment for factors known to increase preeclampsia risks, such as age, parity, race, and weight. 26, 27 There are a number of observations that support the biological plausibility of this association. These include the cardiovascular effects of abnormal concentrations of thyroid hormones, the adverse pregnancy outcomes reported for women with overt hypothyroidism, other vascularrelated pregnancy complications that have been linked to subclinical hypothyroidism, and, finally, endothelial cell activation from abnormal amounts of thyroid hormones.
Regarding the first observation, there are welldocumented widespread cardiovascular effects in nonpregnant women who secrete abnormal amounts of thyroid hormones. Those that are genomically mediated include transcription of structural and regulatory proteins within myocytes that stimulate cell growth.
1 Nongenomic direct T 4 actions include increased cardiac contractility and decreased systemic
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Severe hypertension P=.003 vascular resistance. Also, with prolonged exposure to either abnormally excessive or decreased amounts of hormone, ventricular hypertrophy can lead to heart failure. 1, 2, 28 Up to one fourth of overtly hypothyroid individuals are hypertensive, with a decreased pulse pressure, slowed diastolic filling, decreased ventricular filling and contractility, and increased systemic vascular resistance.
1,2 Although less well-studied, there is evidence that subclinical hypothyroidism in some, usually older, patients can cause hypertension, heart failure, and atherosclerotic vascular disease. 1, 6, 8, 29 Finally, subclinical hypothyroidism has been shown to cause endothelial cell dysfunction characterized by diminished nitric oxide production with impaired vasorelaxation. 12 A second observation that strengthens the biological plausibility of a link between subclinical hypothyroidism and preeclampsia is that adverse outcomes are increased in pregnant women with overt thyroid disorders. A number of investigators have reported that pregnancies in women with untreated or poorly controlled thyrotoxicosis have increased incidences of cardiovascular and related complications such as preeclampsia, placental abruption, and heart failure. 3,30 -34 Similarly, reports of pregnant women with untreated overt hypothyroidism describe inordinately high rates of preeclampsia, placental abruption, and heart failure. 30, 33, 34 The third link is derived from large prenatal screening studies designed to ascertain normal serum levels of thyroid-related analytes, as well as to study adverse pregnancy outcomes caused by thyroid disorders. 19, 21, 35 Although in none of these was an association found between subclinical hypothyroidism or hyperthyroidism and preeclampsia, in one study pregnant women with subclinical hypothyroidism had a significant association with placental abruption, which is another vascular-related complication. In this study, such women were observed to have a significant threefold increased risk for placental abruption compared with euthyroid pregnant women. 16 Additionally, in two of these large population-based studies, a significantly increased twofold to threefold risk for placental abruption was reported in women who had abnormally elevated serum antithyroid antibody levels. 15, 16 The unifying theme of these cited studies is that abnormal levels of thyroid hormones can lead to long-term cardiovascular sequelae that are mediated in part by chronic endothelial cell damage. In this regard, preeclampsia is thought to be a syndrome characterized by multiorgan involvement that results from endothelial cell activation. 36 Thus, it seems reasonable to posit that abnormal levels of thyroid hormones are additive or synergistic toward the development of preeclampsia in women genetically predisposed. 37 As such, the effects of subclinical hypothyroidism are similar to those observed in other maternal conditions characterized by chronic endothelial activation with an increased risk for preeclampsia. Some of these underlying conditions include obesity and the metabolic syndrome, chronic hypertension, diabetes, and renal disease. 27, [37] [38] [39] The strengths of this study are principally related to the number of women enrolled. Specifically, even after adjusting for maternal age, race, parity, and weight, the association of subclinical hypothyroidism and severe preeclampsia remains significant. Conversely, there are three weaknesses that are apparent. One is that the majority of women are of Hispanic heritage, and thus our observations may not be applicable in other ethnic populations. A second is that our database precluded identification of women with chronic hypertension or other such risk factors that are known to increase the risk for preeclampsia. Finally, because height was not recorded for all women enrolled in the first part of the study, we adjusted using weight as a continuous variable instead of body mass index, which many consider to be a more accurate indicator of obesity.
What are the implications of this persistent association between subclinical hypothyroidism and se- vere preeclampsia? We are of the opinion that our findings are more biologically significant than clinically relevant. Our observations add to accruing data that subclinical hypothyroidism, a relatively common finding in women of childbearing age, may be associated with some adverse perinatal outcomes. Nonetheless, we remain convinced that routine prenatal screening for thyroid disorders should not be implemented until clear benefit is established. The Eunice Kennedy Shriver National Institute of Child Health and Human Development-sponsored randomized intervention trial of women identified to have subclinical thyroid disorders currently being conducted by the Maternal-Fetal Medicine Units Network may provide such data.
